Vivodyne, a biotech startup, is addressing the data limitations in AI drug discovery with its modular robotic labs, HIVE. These labs can grow various human tissues and autonomously conduct experiments, generating crucial biological data that current AI models lack, which often rely on less relevant animal testing or isolated studies.
The company claims its tissues closely mimic human organ behavior, achieving high predictive accuracy in toxicity tests. With significant funding and the opening of a large human data center, Vivodyne seeks to enhance drug development efficiency and improve the reliability of clinical trials.